시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 전이성 유방암 치료 시장 보고서(2025년)
Metastatic Breast Cancer Treatment Global Market Report 2025
상품코드 : 1824294
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

세계의 전이성 유방암 치료 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년까지 CAGR 11.5%로 확대되어 345억 4,000만 달러로 성장할 것으로 예상됩니다. 예측 기간의 성장은 표적 치료의 진보, 개인화된 의료 동향, 이환율 증가, 혁신적인 치료에 대한 세계의 접근으로 인한 것으로 예측됩니다. 예측기간의 주요 동향에는 모니터링을 위한 액체생검, 환자 중심의 접근법, 지지요법의 강화, 혁신적인 치료에 대한 접근 확대, 공동 연구 이니셔티브 등이 포함됩니다.

향후 5년간의 성장률 11.5%라는 예측은 지난 예측으로부터 0.2% 소폭 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역마찰에 의해 스위스나 영국에서 개발된 CDK4/6 억제제나 PARP 억제제의 가격이 상승하고, 표적치료 개시 지연과 암 전문 약국의 지출 증가를 초래하여 미국의 암 치료에 지장을 초래할 가능성이 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 보다 광범위하게 이어질 수 있습니다.

예상되는 유방암 이환율의 상승이 당면 전이성 유방암 치료 시장의 성장을 견인할 것으로 보입니다. 유방암은 유방의 세포에서 발생하는 암의 일종으로, 비정상적인 세포가 제어 불능한 성장을 이루고 종양을 형성함으로써 개발됩니다. 이 발생은 유전적 요인, 호르몬 균형의 혼란, 라이프 스타일 및 환경 요소에 의해 영향을받습니다. 전이성 유방암 치료는 유방암의 유병률 관리, 치료 성적 향상, 진행기 질환에 직면하는 사람들의 삶의 질 향상에 공헌하고 있습니다. 2023년 9월 미국암 협회가 발표한 보고서에 따르면 같은 해에는 약 29만 7,790명의 여성이 침윤성 유방암으로 진단되고, 또한 5만 5,720명의 유관암(DCIS)이 새로 발병할 것으로 예측되고 있습니다. 또한 2023년에는 약 4만 3,700명의 여성이 유방암으로 목숨을 잃을 것으로 추정되고 있습니다. 그 결과 유방암의 유병률 증가가 전이성 유방암 치료 시장 성장의 원동력이 되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

JHS
영문 목차

영문목차

Metastatic breast cancer treatment involves medical interventions and therapies aimed at managing breast cancer that has spread (metastasized) from the breast to other parts of the body. The primary objectives of treating metastatic breast cancer are to maximize the patient's survival duration with the disease.

The main types of metastatic breast cancer treatment include chemotherapy, radiation therapy, biologic-targeted therapy, breast surgery, and hormone therapy. Chemotherapy utilizes drugs designed to kill or inhibit the growth of rapidly dividing cells, including cancer cells. It achieves this by targeting the DNA or essential processes of these cells. In the context of metastatic breast cancer treatment, chemotherapy aims to kill or control cancer cells throughout the body, utilizing specific drugs that circulate in the bloodstream. Various types of molecules, such as monoclonal antibodies, peptides, polymers, small molecules, and gene therapy, are administered through oral or parenteral routes by healthcare facilities such as hospitals, clinics, ambulatory surgical centers, and other end-users.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The metastatic breast cancer treatment market research report is one of a series of new reports from The Business Research Company that provides metastatic breast cancer treatment market statistics, including the metastatic breast cancer treatment industry global market size, regional shares, competitors with a metastatic breast cancer treatment market share, detailed metastatic breast cancer treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the metastatic breast cancer treatment industry. This metastatic breast cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metastatic breast cancer treatment market size has grown rapidly in recent years. It will grow from $20.08 billion in 2024 to $22.35 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to advancements in systemic therapies, clinical trial success, improved diagnostic tools, patient advocacy and education.

The metastatic breast cancer treatment market size is expected to see rapid growth in the next few years. It will grow to $34.54 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to targeted therapies advancements, personalized medicine trends, rising incidence rates, global access to innovative therapies. Major trends in the forecast period include liquid biopsy for monitoring, patient-centric approaches, enhanced supportive care, expanded access to innovative therapies, collaborative research initiatives.

The forecast of 11.5% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. cancer care by inflating prices of CDK4/6 inhibitors and PARP inhibitors developed in Switzerland and the UK, resulting in delayed targeted therapy initiation and higher oncology specialty pharmacy expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in breast cancer prevalence is set to drive the growth of the metastatic breast cancer treatment market in the foreseeable future. Breast cancer, a type of cancer originating in the cells of the breast, develops as abnormal cells undergo uncontrolled growth, forming tumors. This occurrence is influenced by genetic factors, hormonal imbalances, lifestyle, and environmental elements. Metastatic breast cancer treatment contributes to managing the prevalence of breast cancer, enhancing outcomes, and improving the quality of life for individuals facing advanced-stage disease. As per a September 2023 report from the American Cancer Society, approximately 297,790 women are expected to be diagnosed with invasive breast cancer in the same year, with an additional 55,720 new cases of ductal carcinoma in situ (DCIS) projected. The report also estimates that around 43,700 women will succumb to breast cancer in 2023. Consequently, the increasing prevalence of breast cancer stands as a driving force behind the growth of the metastatic breast cancer treatment market.

The surge in the geriatric population is poised to bolster the growth of the metastatic breast cancer treatment market. The geriatric population, typically defined as individuals aged 65 or older, is witnessing an upward trend, contributing significantly to the demand for metastatic breast cancer treatments. With age being a notable risk factor for developing metastatic breast cancer, addressing the unique needs of this demographic becomes crucial for sustained market growth. As indicated in an October 2022 report from the World Health Organization (WHO), it is projected that by 2030, one out of every six individuals globally will be 60 years old or older. The estimate further predicts that by 2050, there will be 2.1 billion people worldwide falling into this age bracket. Hence, the increase in the geriatric population emerges as a key driver for the growth of the metastatic breast cancer treatment market.

The introduction of advanced therapeutic remedies is a prominent trend gaining traction in the metastatic breast cancer treatment market. Major companies in this market are actively advancing therapeutic remedies as part of their strategy to maintain a competitive position. An example is BDR Pharmaceuticals Internationals Pvt. Ltd., an India-based pharmaceutical company that launched Palbociclib, branded as 'BDPALBO' in India. BDPALBO, a generic version of palbociclib, offers a cost-effective treatment option for patients diagnosed with metastatic breast cancer.

Innovation in product development, particularly monoclonal antibodies (mAbs), is a key focus for major companies operating in the metastatic breast cancer treatment market. Monoclonal antibodies, laboratory-produced molecules mimicking the immune system's ability to combat pathogens, are gaining prominence. Roche Pharma, a Switzerland-based pharmaceutical company, introduced PHESGO in India in May 2022. PHESGO, a groundbreaking formulation, combines two monoclonal antibodies, Perjeta (pertuzumab) and Herceptin (trastuzumab), along with hyaluronidase, providing a streamlined treatment approach for both early and metastatic HER2-positive breast cancer. This innovation aims to enhance treatment efficiency and patient convenience, incorporating the benefits of multiple monoclonal antibodies into a more accessible and patient-friendly delivery method.

In April 2023, Pfizer Inc., a US-based biotechnology and pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition enhances Pfizer's oncology portfolio by incorporating antibody-drug conjugate (ADC) technology for the development of drug programs. Seagen Inc., a US-based biotechnology company, is known for its contributions to metastatic triple-negative breast cancer treatment.

Major companies operating in the metastatic breast cancer treatment market include Pfizer Inc., AstraZeneca plc, Novartis AG, Eli Lilly & Co., Merck & Co. Inc., Johnson & Johnson Services Inc., Sun Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Bayer Aktiengesellschaft ., Bristol-Myers Squibb Company, Boehringer Ingelheim Gmbh, Aslan Pharmaceuticals Pte. Ltd., AbbVie Inc., Eisai Co. ltd., Seattle Genetics Inc., Immunomedics Inc., Genentech Inc., MacroGenics Inc., Daiichi Sankyo Company Lmited, Takeda Pharmaceutical Company Lmited, Celgene Corporation, Exelixis Inc., Array BioPharma Inc., Athenex Inc., Clovis Oncology Inc., Cyclacel Pharmaceuticals Inc., Immunovative Therapies Ltd., Inovio Pharmaceuticals Inc., Karyopharm Therapeutics Inc., Mersana Therapeutics Inc., Nektar Therapeutics Inc.

North America was the largest region in the metastatic breast cancer treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global metastatic breast cancer treatment market during the forecast period. The regions covered in the metastatic breast cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the metastatic breast cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The metastatic breast cancer treatment market includes revenues earned by entities by immunotherapy, and targeted therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Metastatic Breast Cancer Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on metastatic breast cancer treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for metastatic breast cancer treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The metastatic breast cancer treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Metastatic Breast Cancer Treatment Market Characteristics

3. Metastatic Breast Cancer Treatment Market Trends And Strategies

4. Metastatic Breast Cancer Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Metastatic Breast Cancer Treatment Growth Analysis And Strategic Analysis Framework

6. Metastatic Breast Cancer Treatment Market Segmentation

7. Metastatic Breast Cancer Treatment Market Regional And Country Analysis

8. Asia-Pacific Metastatic Breast Cancer Treatment Market

9. China Metastatic Breast Cancer Treatment Market

10. India Metastatic Breast Cancer Treatment Market

11. Japan Metastatic Breast Cancer Treatment Market

12. Australia Metastatic Breast Cancer Treatment Market

13. Indonesia Metastatic Breast Cancer Treatment Market

14. South Korea Metastatic Breast Cancer Treatment Market

15. Western Europe Metastatic Breast Cancer Treatment Market

16. UK Metastatic Breast Cancer Treatment Market

17. Germany Metastatic Breast Cancer Treatment Market

18. France Metastatic Breast Cancer Treatment Market

19. Italy Metastatic Breast Cancer Treatment Market

20. Spain Metastatic Breast Cancer Treatment Market

21. Eastern Europe Metastatic Breast Cancer Treatment Market

22. Russia Metastatic Breast Cancer Treatment Market

23. North America Metastatic Breast Cancer Treatment Market

24. USA Metastatic Breast Cancer Treatment Market

25. Canada Metastatic Breast Cancer Treatment Market

26. South America Metastatic Breast Cancer Treatment Market

27. Brazil Metastatic Breast Cancer Treatment Market

28. Middle East Metastatic Breast Cancer Treatment Market

29. Africa Metastatic Breast Cancer Treatment Market

30. Metastatic Breast Cancer Treatment Market Competitive Landscape And Company Profiles

31. Metastatic Breast Cancer Treatment Market Other Major And Innovative Companies

32. Global Metastatic Breast Cancer Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Metastatic Breast Cancer Treatment Market

34. Recent Developments In The Metastatic Breast Cancer Treatment Market

35. Metastatic Breast Cancer Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기